Harnessing neoantigen-specific T cells for precision cancer immunotherapy

Nature Reviews Clinical Oncology, Published online: 19 January 2024; doi:10.1038/s41571-024-00860-8Several novel personalized therapies focus on targeting neoantigens. Such strategies require the identification of suitable vaccine neoepitopes or neoantigen-specific T cell receptor (TCR) clonotypes. Herein, we discuss a recently published report that describes a combined transcriptional and phenotype signature, NeoTCRPBL, that enables the minimally invasive identification of rare neoantigen-specific TCRs from peripheral blood that might enable more-effective T cell-based therapies against cancer.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research